Ubs Group Ag Rallybio Corp Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
A detailed history of Ubs Group Ag transactions in Rallybio Corp stock. As of the latest transaction made, Ubs Group Ag holds 2,342 shares of RLYB stock, worth $2,318. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,342
Previous 10,641
77.99%
Holding current value
$2,318
Previous $14,000
85.71%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RLYB
# of Institutions
52Shares Held
31.9MCall Options Held
0Put Options Held
0-
Viking Global Investors LP4.19MShares$4.15 Million0.02% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.64MShares$3.6 Million1.36% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA3.63MShares$3.59 Million1.69% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY3.3MShares$3.27 Million3.98% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX3.03MShares$3 Million0.08% of portfolio
About Rallybio Corp
- Ticker RLYB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,132,000
- Market Cap $31.8M
- Description
- Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...